Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2345176 | 0.89 | KMT2A (0.40) | TSHRMAPTL3MBTL1KAT2BLMNA | |
| SCHEMBL15876199 | 0.77 | MAPT (0.46) | HPGDMAPTL3MBTL1KAT2BMIF | |
| SCHEMBL4418335 | 0.76 | TYR (0.57) | TSHRMAPTTYR | |
| SCHEMBL28747388 | 0.75 | CYP4F2 (0.55) | HPGDTSHRCYP4F2CYP4A11LMNA | |
| SCHEMBL31155814 | 0.75 | CYP4F2 (0.55) | HPGDTSHRCYP4F2CYP4A11LMNA | |
| SCHEMBL9129463 | 0.75 | HPGD (0.52) | HPGDTSHRMAPTTYR | |
| SCHEMBL27551717 | 0.74 | IAPP (0.49) | — | |
| SCHEMBL70495 | 0.74 | TYR (0.56) | HPGDTSHRMAPTTYR | |
| SCHEMBL9128626 | 0.74 | ALDH1A1 (0.55) | HPGDTYRMIF | |
| SCHEMBL10732614 | 0.73 | CNR1 (0.44) | HPGDTSHRMAPTL3MBTL1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541454-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541454-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541454-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20050159606-A1 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2005-07-21 | — | — | US | disclosed |
| WO-2005040357-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159606-A1 | Compounds and methods for fluorescent labeling | TFEB, HLCS, PFAS | HPGD 1511/4885TSHR 4324/4885MAPT 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.